Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Acadia Pharmaceuticals Inc shares valued at $670,983 were sold by Daly James M on Nov 10 ’25. At $22.37 per share, Daly James M sold 30,000 shares. The insider’s holdings dropped to 4,041 shares worth approximately $97509.33 following the completion of this transaction.
Also, James M Daly purchased 30,000 shares, netting a total of over 670,983 in proceeds.
Before that, Schneyer Mark C. had sold 3,498 shares from its account. In a trade valued at $82,728, the EVP, CHIEF FINANCIAL OFFICER traded Acadia Pharmaceuticals Inc shares for $23.65 each. Upon closing the transaction, the insider’s holdings decreased to 3,498 shares, worth approximately $1.05 million.
As published in their initiating research note from Citigroup on October 21, 2025, Acadia Pharmaceuticals Inc [ACAD] has been a Buy and the price target has been revised to $33. Analysts at Deutsche Bank upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in late May. As of February 11, 2025, Deutsche Bank has initiated its “Hold” rating for ACAD. Earlier on January 03, 2025, Guggenheim downgraded its rating. Their new recommendation was “a Neutral” for ACAD stock which previously was a “a Buy”.
Analyzing ACAD Stock Performance
On last trading session, Acadia Pharmaceuticals Inc [NASDAQ: ACAD] rose 1.73% to $24.13. The stock’s lowest price that day was $23.38, but it reached a high of $24.39 in the same session. During the last five days, there has been a surge of approximately 8.06%. Over the course of the year, Acadia Pharmaceuticals Inc shares have jumped approximately 36.64%. Shares of the company reached a 52-week high of $26.65 on 08/28/25 and a 52-week low of $13.40 on 04/09/25.
Support And Resistance Levels for Acadia Pharmaceuticals Inc (ACAD)
According to the 24-hour chart, there is a support level at 23.54, which, if violated, would cause prices to drop to 22.96. In the upper region, resistance lies at 24.55. The next price resistance is at 24.98. RSI (Relative Strength Index) is 63.35 on the 14-day chart, showing neutral technical sentiment.
Is Acadia Pharmaceuticals Inc subject to short interest?
Stocks of Acadia Pharmaceuticals Inc saw a sharp steep in short interest on 2025-10-31 dropping by -0.9 million shares to 8.51 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 9.41 million shares. A decline of -10.54% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.36 of the overall float, the days-to-cover ratio (short ratio) decline to 4.36.
Which companies own the most shares of Acadia Pharmaceuticals Inc (ACAD)?
In terms of Acadia Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 29.5 in the next 12 months, up nearly 24.37% from the previous closing price of $23.72. Analysts anticipate Acadia Pharmaceuticals Inc stock to reach 39 by 2025, with the lowest price target being 22. In spite of this, 16 analysts ranked Acadia Pharmaceuticals Inc stock as Buy at the end of 2025.
